need increas revenu along focus cost control
initi coverag hold rate
price target estim non ep
forward look pe
per view consid
consist growth per guidanc deliv convinc
quarter strong volum growth volum driven growth
new product show result long term
count growth new product
non-gaap oper incom growth non-
gaap ep growth great initi
expect top line revenu growth least y/i
current flat y/i order compet peer
total revenu quarter increas
y/i compar total product
revenu increas y/i compar
increas revenu mainli driven prolia
sensipar/mimpara repatha kyproli revenu
increas y/i compar
increas driven primarili higher ibranc
total product revenu quarter increas
compar increas
due volume-driven growth recent launch
product includ prolia repatha kyproli
sale grew exclud neg impact foreign exchang
double-digit volum growth europ
geograph wise total product sale
increas y/i compar
total sale rest world
quarter increas compar
compani nameamgen inc tickeramgnstock ratingholdiniti coverageindustri viewoverweightpositivepric coveragecurr market price week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth
incom statement
guidanc
per share item
product perform develop
valuat consensu perform
net incom compar
increas y/i net margin
quarter compar
increas driven primarili higher oper margin
ep compar
increas y/i
revenu growth end rel
flat compar howev
saw increas oper net margin
transform effort reduc cost paid
oper incom net incom increas
respect
ep grew major growth seen
due increas net margin cash
reserv flat first half
mid point in-lin
perform end first half rais
bar full year guidanc compani
narrow revenu guidanc
compani rais non-gaap ep guidanc
compani expect non-gaap tax rate
capit expenditur unchang previou
conclus saw good quarter result strong
volume-driven growth recent launch product
end quarter strong cash flow execut
capit alloc program transform effort
reduc cost deliv effici effect
receiv mani fda approv product
strong pipelin product repatha kiproli
sensipar achiev higher sale quarter
also submit mani sbla fda remain posit
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date sep ex-dividend date aug last split factor new per last split date inform
incom statement
guidanc
per share item
product perform develop
valuat consensu perform
incom statement month end month end month end month end month end month end month end month end month end month end month end revenu revenu expens expens incom net expens oper expens oper incom expens net loss sale incom extra avail common excl extra avail common incl extra weight averag ep exclud extraordinari ep includ extraordinari weight averag ep exclud extraordinari ep includ extraordinari per share common stock primari dividend common incom stock base comp ep stock base comp ep stock base comp special incom special item incom tax ex impact special incom incom avail normal normal annual estim annual actual quarterli
 term short term receiv trade receiv current asset current total term long term asset payable/short term port lt debt/capit current liabil current term leas long term incom liabil prefer stock stock non redeem stock paid-in earn accumul stock equiti liabil sharehold out common stock primari common share annual actual quarterli balanc sheet item
six month end june repurchas paid cash stock
period
cash equival market secur june
month end month end month end month end month end month end month end month end income/start work oper invest item invest dividend retir stock retir debt financ exchang chang interest paid tax paid
announc result strong growth net margin
ep mani product receiv fda approv amgn product pipelin
grown stronger saw effici reduc cost achiev
good number end first half track achiev
object set adjust ep quarter beat
estim
total revenu quarter increas y/i
compar
total product revenu increas y/i compar
increas revenu mainli driven prolia
sensipar/mimpara repatha kyproli
revenu increas y/i compar
increas driven primarili higher ibranc palbociclib
cog quarter decreas y/i compar
decreas mainli due lower royalti
quarter gross margin compar
sg expens quarter compar
decreas y/i mainli due expir enbrel
residu royalti payment octob off-set partial invest
product launch
 expens quarter compar
decreas y/i mainli due lower spend requir
support certain later-stag clinic program decreas
ebit increas y/i compar
oper margin stood compar
increas due decreas oper expens
total revenu
quarter
increas
y/i compar
sg expens
quarter
compar
compar
net incom
compar
increas
y/i ep
compar
increas
ep grew
major growth seen
due
increas net margin
month end mn except per share item
net incom compar
increas y/i net margin quarter compar
increas driven primarili higher oper margin
ep compar increas
tabl show perform end
revenu growth end rel flat compar
howev saw increas oper net margin
transform effort reduc cost paid oper
incom net incom increas respect
ep grew major growth seen due
increas net margin cash reserv flat first half
respect
major product enbrel neulasta aranesp prolia
denosumab sensipar/mimpara xgeva epogen product includ
evolocumab blincyto blinatumomab imlyg corlanor ivabradin
total product revenu quarter increas
compar increas due volume-driven
growth recent launch product includ prolia repatha
kyproli sale grew exclud neg impact foreign
exchang double-digit volum growth europ
geograph wise total product sale
increas y/i compar total sale rest
world quarter increas compar
total world-wide sale
y/i
compar
total world-wide sale
y/i
compar
kyproli
surviv improv
endeavor
total world-wide sale increas y/i compar
sale grew y/i sale
rest world increas
increas mainli due new patient start sustain strong
expect prolia remain signific growth driver forese
futur larg unmet need patient still risk fractur
total world-wide sale increas y/i compar
sale declin y/i sale
rest world doubl
increas mainli due strong y/i unit growth driven ex-u
launch
kyproli demonstr overal surviv improv
endeavor studi focus displac
velcad second-lin multipl myeloma
changenet sale mn rowtotaltot product excess includ bergamo mn pharma imlyg
total world-wide sale
compar
total world-wide sale
y/i
compar
total world-wide sale
y/i
compar
total world-wide sale increas y/i compar
sale grew y/i sale
rest world decreas
increas mainli due y/i volum growth driven focu superior
clinic profil versu competit
expect add multipl myeloma indic
total world-wide sale increas y/i compar
sale grew y/i sale
rest world increas
increas mainli due y/i sale growth driven higher volum unit
total world-wide sale increas y/i compar
sale grew y/i sale
rest world decreas
increas due y/i sale growth driven primarili higher unit
demand vectibix share epiderm growth factor
receptor egfr segment grow label includ expand ra
total world-wide sale decreas y/i compar
sale declin y/i sale
rest world decreas
decreas due low single-digit declin usag myelosuppress
chemotherapi regimen due new immunotherapi
june util neulasta onpro kit continu grow
unit state
total world-wide sale
y/i
compar
total world-wide sale
y/i
compar
total world-wide sale
y/i
compar
total world-wide sale declin y/i compar
sale declin y/i sale
rest world decreas
decreas due unit declin driven short-act biosimilar
competit expect competit dynam continu
total world-wide sale decreas y/i compar
sale declin y/i sale
rest world decreas
decreas due lower unit demand off-set partial chang
end-custom inventori net sell price improv seen
growth rate rheumatolog dermatolog segment
total world-wide sale increas y/i compar
sale increas y/i
sale rest world increas
increas due y/i growth primarili unit includ benefit
time tender certain market outsid
aranesp may face short-act competit propos biosimilar
total sale decreas y/i compar
decreas due y/i sale declin driven net sell price primarili
due extend suppli agreement davita
face competit unit state
continu materi advers impact sale epogen
total world-wide sale
compar
total world-wide sale
repatha tripl y/i
compar
total world-wide sale
y/i
compar
total world-wide sale grew y/i compar
sale increas y/i sale
rest world decreas
increas y/i sale growth driven primarili net sell price
lesser extent unit growth parsabiv approv europ
continu await parsabiv reimburs guidanc
total world-wide sale tripl y/i compar
sale rest world tripl
respect
increas due increas unit sale continu extend
segment leadership europ
look forward public updat expert
total world-wide sale increas y/i compar
sale increas y/i sale
rest world increas
product world-wide sale includ bergamo mn pharma
imlyg corlanor decreas y/i compar
sale increas y/i sale rest world
decreas
follow signific develop
affect busi
may ucb global collabor partner
develop even announc even activecon-
troll fractur studi postmenopaus women osteoporosi high
risk fractur studi met primari endpoint key secondari
endpoint imbal posit adjud cardiovascular seriou
advers event observ new safeti signal
juli ucb announc fda issu complet
respons letter biolog licens applic bla even
treatment postmenopaus women osteoporosi resubmiss
includ data phase studi phase bridg
placebo-control studi evalu efficaci safeti
romosozumab treat men osteoporosi studi evalu even
men osteoporosi addit phase frame fractur studi
postmenopaus women osteoporosi studi
june announc submiss sbla fda
variat market author european medicin agenc
ema repatha regulatori submiss base repatha
juli announc fda accept review bla
aimovig prevent migrain patient experienc four
migrain day per month fda set pdufa target action date
may aimovig develop commerci jointli
may
ucb announc
primari endpoint
key secondari
announc
submiss sbla
fda variat
market
author
agenc ema
juli announc fda approv sbla
blincyto includ overal surviv data phase tower studi
approv convert blincyto acceler approv full approv
approv expand indic blincyto treatment
relaps refractori b-cell precursor acut lymphoblast leukemia
adult children
juli announc posit result final analysi
phase carfilzomib lenalidomid dexamethason versu
lenalidomid dexamethason treatment patient
relaps multipl myeloma studi studi met key secondari
endpoint overal surviv demonstr kyproli lenalidomid
dexamethason reduc risk death lenalidomid
juli announc submiss supplement new drug
applic fda variat market applic
ema includ overal surviv data phase head-to-head
endeavor random open label phase studi carfilzomib
dexamethason vs bortezomib dexamethason patient
relaps multipl myeloma studi product label kyproli
juli phase studi kyproli combin darzalex
daratumumab dexamethason compar kyproli
dexamethason alon began enrol patient relaps refractori
june announc fda approv label updat
vectibix precis molecularli defin patient wild-typ ra
metastat colorect cancer first-lin therapi combin
folfox monotherapi follow diseas progress prior
treatment fluoropyrimidin oxaliplatin irinotecan-contain
announc fda
approv sbla
blincyto includ
phase tower
announc
submiss
applic fda
variat
market applic
ema includ
phase head-
juli fda oncolog drug advisori committe vote
unanim recommend approv abp biosimilar candid
avastin bevacizumab fda bound committe
recommend take advic consider
consid approv new therapeut fda set biosimilar
user fee act target action date septemb abp
develop collabor allergan plc
may amgen next-gener biomanufactur plant singapor
approv fda commerci product denosumab drug
tabl summar pipelin mileston
relaps refractori multipl myeloma
prevent sre multipl myeloma
guidanc conclus
updat full year guidanc mid point in-lin
perform end first half rais bar
compani narrow revenu guidanc
compani rais non-gaap ep guidanc
compani expect non-gaap tax rate capit expenditur
saw good quarter result strong volume-driven growth
recent launch product end quarter strong cash flow
execut capit alloc program transform effort reduc
cost deliv effici effect
receiv mani fda approv product strong pipelin
product repatha kiproli sensipar achiev higher sale
quarter also submit mani sbla fda remain posit
oper margin net margin quarter
respect roa roe roi respect
ep quarter
compani
narrow revenu
guidanc
compani rais
roa roe roi
ep quarter
incom statement
guidanc
per share item
product perform develop
valuat consensu perform
oper margin increas ttm basi compar
net margin increas ttm basi compar
cog sg respect ttm basi
ratio margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth
mrqgross mrqcog mrqsg mrqoper mrqnet mrqr sale
invest flow
sale
mrqfinanci mrqreturn mrqreturn mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqyoy growth revenu growthoper incom growthep growth
per share item ratio
per share itemsfisc per per per per share cash-flow per per valu per book per end stock end stock ratiosreturn equiti asset invest capit capit joel greenblatt margin margin margin equiti total debt total pay-out sale account convers rate incom incom margin itemsquarterli item
itemsshar outstand equival market properti plant properti plant issuanc prefer issuanc chang
incom statement
guidanc
per share item
product perform develop
valuat consensu perform
breakdown share held insid share held institut mutual fund float held institut mutual fund institut hold direct holder form robert anthoni brian sean david jonathan vanc institut holdersholdershar report outvaluefmr capit research global vanguard group inc primecap manag northern trust morgan clearbridg invest top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard/primecap invest compani capit world growth incom vanguard spdr etf vanguard institut fund-institut capit incom builder growth fund america amcap
develop partner improv health outcom efficiencytwo nation lead health organ inc biotechnolog compani team identifi opportun improv health outcom improv effici unlock new insight real world health care experi member collabor agreement six project current underway plan expect term agreement organ commit expand work therapeut area partnership bring valu repatha evolocumab phase cognit function studi result publish new england journal medicin announc new england journal medicin nejm publish result repatha evolocumab cognit function trial ebbinghau conduct subset patient enrol random placebo-control repatha cardiovascular outcom studi fourier studi demonstr repatha non-inferior placebo signific differ cognit function repatha placebo-tr group submit supplement biolog licens applic prolia denosumab glucocorticoid-induc osteoporosi jul announc submiss supplement biolog licens applic sbla food drug administr fda prolia denosumab treatment patient glucocorticoid-induc osteoporosi giop sbla base phase studi evalu safeti efficaci prolia compar risedron patient receiv glucocorticoid treatment allergan submit biosimilar biolog licens applic abp us food drug administr jul allergan plc announc submiss biolog licens applic bla food drug administr fda abp biosimilar candid herceptin trastuzumab allergan collabor four oncolog biosimilar medicin includ abp second submit fda approv fda grant prioriti review supplement biolog licens applic repatha evolocumab includ data reduc risk cardiovascular event jul announc theu food drug administr fda grant prioriti review ssupplement biolog licens applic sbla repatha evolocumab inhibitor approv thefda prescrib inform repatha updat includ risk reduct major cardiovascular event base data larg cardiovascular outcom studi fourier thefdaha set prescript drug user fee act pdufa action date ofdec
incom statement
guidanc
per share item
product perform develop
valuat consensu perform
price-to-earnings ratio ttm
sector multipl
industri
multipl
sale growth
compar sector
averag
profit ratio
encourag gross
margin
sector averag
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit
consensu view analyst trend stock
forecast
forecast
forward price-to-earnings ratio
compar
 average
amgn avgfive-year growth forecast usdgrowth high day day day estim comparisonamgnindustri avg avgprice/earn yield
consensu view analyst trend stock
next earn growth
estim
revenu growth estim
decreas
respect
ep estim
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last daysn/an/an/an/adown last dayscurr growth ratescurr surprisescurr
price target summarycrispidea trendscurr monthlast monthtwo month agothre month agostrong estcurr qtr next qtrcurrent yearnext estcurr qtr next qtrcurrent yearnext
incom statement
guidanc
per share item
product perform develop
valuat consensu perform
stock given consist return past month seen sudden rise price mid june
level level
volum consist quarterli period stock reach high june
huge dip seen stock oct fall level level reach low
stock recov level reach high juli
stock reach all-tim high given return last year
stock shown signific price fluctuat either side last year
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
